BHC Stock Analysis: Buy, Sell, or Hold?
BHC - Bausch Health Companies Inc
$4.85
0.07 (1.46%)
▲
5d:
+0.83%
30d:
-5.83%
90d:
-13.39%
BUY
HIGH Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Jul 29, 2026
14d
Smart Money Accumulation
None View Scanner →
Strength: 7.0/10
Get Alerted When BHC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called BHC this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: BHC appears deeply undervalued. Market expects -6.5% annual earnings decline despite 1368% recent earnings growth. Contrarian opportunity at discount to historical valuation.
✅ BUY SIGNAL: BHC appears deeply undervalued. Market expects -6.5% annual earnings decline despite 1368% recent earnings growth. Contrarian opportunity at discount to historical valuation.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$5.80
Based on -0.3% avg growth
INTRINSIC VALUE TODAY
$3.60
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 1.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BHC is currently trading at $4.85, which is considered slightly low relative to its 30-day fair value range of $4.77 to $5.14. From a valuation perspective, the stock is trading at a discount (Forward PE: 1.1) compared to its historical average (1.4). Remarkably, the market is currently pricing in an annual earnings decline of 6.5% over the next few years. This pessimistic expectation contrasts with the company's recent 1368.0% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, BHC is in a strong uptrend. Immediate support is located at $4.63, while resistance sits at $5.02.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.40 (+52.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BHC is in a strong uptrend. Immediate support is located at $4.63, while resistance sits at $5.02.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $7.40 (+52.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$4.77 -
$5.14
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 52.6% below Wall St target ($7.40)
Trading Range Analysis
30-Day Trading Range
$4.77 -
$5.14
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$4.63
Resistance Level
$5.02
Current Trend
Strong Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
1.15
Wall Street Target
$7.40
(+52.6%)
Revenue Growth (YoY)
11.7%
Earnings Growth (YoY)
1368.0%
Profit Margin
-11.5%
Valuation Discount vs History
-6.5% cheaper
PE vs Historical
1.2 vs 1.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-6.5%
(market-implied from PE analysis)
1-Year Target
$4.53
(-7%)
2-Year Target
$4.24
(-13%)
3-Year Target
$3.96
(-18%)
3-Yr Target (if PE normalizes)
(PE: 1→1)
$4.83
(-1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: -4.6%)
$79.75
(+1544%)
Base:
(SPY PE: 1.2, Growth: -4.6%)
$4.21
(-13%)
Bear:
(PE: 1.0, Growth: -4.6%)
$3.58
(-26%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 1.2 to 1.4
Stabilization Target:
$5.90
(+21.7%)
PE Expansion Potential:
+21.7%
Share & Embed Analysis
Last updated: July 14, 2026 1:29 AM ET
Data refreshes hourly during market hours. Next update: 2:29 AM
Data refreshes hourly during market hours. Next update: 2:29 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BHC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$198 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$116 | 59 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$110 | 51 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 55 HOLD |
Advanced BHC Option Strategies
Professional options setups generated by AI based on today's BHC price and gamma walls.
